Health Centered Co., Ltd. announced on the 31st that it signed a strategic MOU with pharmaceutical distribution company Dioni Healthcare Co., Ltd. and Curom Bioscience Co., Ltd., a company specializing in the development of new drugs for the treatment of rare and incurable diseases.
Through this collaboration, Health-Centric plans to accelerate the development of NAD+ (nicotinamide adenine dinucleotide) technology and Senolytic-based products. The company aims to lead the market by developing innovative health functional foods that optimize energy metabolism.
Curum Biosciences has a technology that increases intracellular NAD+ levels through an NAD+ promoter called 'HK-660S', which is being developed as a treatment for primary sclerosing cholangitis, and induces ATP production through NQO1 enzyme activation. This technology promotes cellular energy production, exerts anti-inflammatory and anti-fibrotic effects, and contributes to activating energy metabolism. Health Centered is applying this technology to its products to develop innovative health functional foods that combine senolytic effects and energy metabolism optimization.
Dioni Healthcare operates a regenerative cell regulation research group and has established a strong distribution network targeting pharmacies nationwide. It develops and supplies products specialized for member pharmacies and supports the development of new products and market expansion based on consumer feedback and analysis of product effectiveness.
Park Young-ho, CEO of Health-Centered, said, “We will actively utilize Curombioscience’s NAD+ technology and Dioni Healthcare’s distribution capabilities to introduce products that maximize the effects of senolytic technology and energy metabolism optimization.” He added, “This collaboration will be an important opportunity to lead new innovation in the global health functional food market by realizing the goals of optimizing energy metabolism, promoting cell health, and providing consumer-centered solutions.”
You must be logged in to post a comment.